Skip to main content
Erschienen in: Clinical and Experimental Nephrology 6/2011

01.12.2011 | Case Report

Renal complications of Castleman’s disease: report of two cases and analysis of 75 cases

verfasst von: Xiang-Gui Yuan, Wen Hu, Fei-Fei Chen, Bin-Feng Huang, Xiao-Ying Zhao

Erschienen in: Clinical and Experimental Nephrology | Ausgabe 6/2011

Einloggen, um Zugang zu erhalten

Abstract

Biopsy-proven renal complications of Castleman’s disease (CD) are rare and current knowledge is largely based on sporadic case reports. We reported two more cases, both of which were multicentric CD with hyaline-vascular pathological pattern and presented with chronic renal failure. Case 1 was multicentric CD with renal mesangial proliferative glomerulonephritis complications, and case 2 was multicentric CD with membranoproliferative glomerulonephritis-like complications. Although both were eventually administered corticosteroids combined with cytotoxic drugs, both behaved in an aggressive and relapsing manner. We then made an analysis of 75 cases of biopsy-proven renal complications of CD (including our two cases) which were reported in 51 English literatures from January 1954 to March 2011. We found that the clinical and histological findings of renal complications of CD were heterogeneous. Death was observed in 17% patients after a median follow-up time of 22 months (0–204 months) since histological diagnosis of renal complications. The estimated 5-year cumulative survival rate was 75%. Better understanding and therapeutic interventions are required in further investigations.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Cronin DM, Warnke RA. Castleman disease: an update on classification and the spectrum of associated lesions. Adv Anat Pathol. 2009;16:236–46.PubMedCrossRef Cronin DM, Warnke RA. Castleman disease: an update on classification and the spectrum of associated lesions. Adv Anat Pathol. 2009;16:236–46.PubMedCrossRef
2.
Zurück zum Zitat El Karoui K, Vuiblet V, Dion D, Izzedine H, Guitard J, Frimat L, et al. Renal involvement in Castleman disease. Nephrol Dial Transplant. 2011;26:599–609.PubMedCrossRef El Karoui K, Vuiblet V, Dion D, Izzedine H, Guitard J, Frimat L, et al. Renal involvement in Castleman disease. Nephrol Dial Transplant. 2011;26:599–609.PubMedCrossRef
3.
Zurück zum Zitat Castell JV, Gomez-Lechon MJ, David M, Fabra R, Trullenque R, Heinrich PC. Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology. 1990;12:1179–86.PubMedCrossRef Castell JV, Gomez-Lechon MJ, David M, Fabra R, Trullenque R, Heinrich PC. Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology. 1990;12:1179–86.PubMedCrossRef
4.
Zurück zum Zitat Seida A, Wada J, Morita Y, Baba M, Eguchi J, Nishimoto N, et al. Multicentric Castleman’s disease associated with glomerular microangiopathy and MPGN-like lesion: does vascular endothelial cell-derived growth factor play causative or protective roles in renal injury? Am J Kidney Dis. 2004;43:E3–9.PubMedCrossRef Seida A, Wada J, Morita Y, Baba M, Eguchi J, Nishimoto N, et al. Multicentric Castleman’s disease associated with glomerular microangiopathy and MPGN-like lesion: does vascular endothelial cell-derived growth factor play causative or protective roles in renal injury? Am J Kidney Dis. 2004;43:E3–9.PubMedCrossRef
5.
Zurück zum Zitat Kazes I, Deray G, Jacobs C. Castleman disease and renal amyloidosis. Ann Intern Med. 1995;122:395–6.PubMed Kazes I, Deray G, Jacobs C. Castleman disease and renal amyloidosis. Ann Intern Med. 1995;122:395–6.PubMed
6.
Zurück zum Zitat Humpherys SR, Holley KE, Smith LH, McIlrath DC. Mesenteric angiofollicular lymph node hyperplasia (lymphoid hamartoma) with nephrotic syndrome. Mayo Clin Proc. 1975;50:317–21.PubMed Humpherys SR, Holley KE, Smith LH, McIlrath DC. Mesenteric angiofollicular lymph node hyperplasia (lymphoid hamartoma) with nephrotic syndrome. Mayo Clin Proc. 1975;50:317–21.PubMed
7.
Zurück zum Zitat Ruggieri G, Barsotti P, Coppola G, Spinelli C, Balducci A, Ventola FR, et al. Membranous nephropathy associated with giant lymph node hyperplasia. A case report with histological and ultrastructural studies. Am J Nephrol. 1990;10:323–8.PubMedCrossRef Ruggieri G, Barsotti P, Coppola G, Spinelli C, Balducci A, Ventola FR, et al. Membranous nephropathy associated with giant lymph node hyperplasia. A case report with histological and ultrastructural studies. Am J Nephrol. 1990;10:323–8.PubMedCrossRef
8.
Zurück zum Zitat Perfetti V, Bellotti V, Maggi A, Arbustini E, De Benedetti F, Paulli M, et al. Reversal of nephrotic syndrome due to reactive amyloidosis (AA-type) after excision of localized Castleman’s disease. Am J Hematol. 1994;46:189–93.PubMedCrossRef Perfetti V, Bellotti V, Maggi A, Arbustini E, De Benedetti F, Paulli M, et al. Reversal of nephrotic syndrome due to reactive amyloidosis (AA-type) after excision of localized Castleman’s disease. Am J Hematol. 1994;46:189–93.PubMedCrossRef
9.
Zurück zum Zitat Sugimoto T, Ito J, Takeda N, Gasyu I, Okazaki T, Sakaguchi M, et al. A case of Castleman’s disease complicated with nephrotic syndrome due to glomerulopathy mimicking membranoproliferative glomerulonephritis. Am J Med Sci. 2008;335:495–8.PubMedCrossRef Sugimoto T, Ito J, Takeda N, Gasyu I, Okazaki T, Sakaguchi M, et al. A case of Castleman’s disease complicated with nephrotic syndrome due to glomerulopathy mimicking membranoproliferative glomerulonephritis. Am J Med Sci. 2008;335:495–8.PubMedCrossRef
10.
Zurück zum Zitat Paydas S, Gonlusen G, Sagliker Y. Regression of nephrotic syndrome with colchicine therapy secondary to amyloidosis with associated Castleman’s disease. Nephron. 1995;71:463–4.PubMedCrossRef Paydas S, Gonlusen G, Sagliker Y. Regression of nephrotic syndrome with colchicine therapy secondary to amyloidosis with associated Castleman’s disease. Nephron. 1995;71:463–4.PubMedCrossRef
11.
Zurück zum Zitat Menegato MA, Canelles MF, Tonutti E, Pizzolitto S. Remission of nephrotic syndrome after thalidomide therapy in a patient with Castleman’s disease. Clin Nephrol. 2004;61:352–6.PubMed Menegato MA, Canelles MF, Tonutti E, Pizzolitto S. Remission of nephrotic syndrome after thalidomide therapy in a patient with Castleman’s disease. Clin Nephrol. 2004;61:352–6.PubMed
12.
Zurück zum Zitat Suneja S, Chidambaram M, Herzenberg AM, Bargman JM. Kidney involvement in multicentric Castleman disease. Am J Kidney Dis. 2009;53:550–4.PubMedCrossRef Suneja S, Chidambaram M, Herzenberg AM, Bargman JM. Kidney involvement in multicentric Castleman disease. Am J Kidney Dis. 2009;53:550–4.PubMedCrossRef
13.
Zurück zum Zitat Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244.PubMed Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244.PubMed
14.
Zurück zum Zitat Nasr SH, Satoskar A, Markowitz GS, Valeri AM, Appel GB, Stokes MB, et al. Proliferative glomerulonephritis with monoclonal IgG deposits. J Am Soc Nephrol. 2009;20:2055–64.PubMedCrossRef Nasr SH, Satoskar A, Markowitz GS, Valeri AM, Appel GB, Stokes MB, et al. Proliferative glomerulonephritis with monoclonal IgG deposits. J Am Soc Nephrol. 2009;20:2055–64.PubMedCrossRef
15.
Zurück zum Zitat Ogita M, Hoshino J, Sogawa Y, Sawa N, Katori H, Takemoto F, et al. Multicentric Castleman disease with secondary AA renal amyloidosis, nephrotic syndrome and chronic renal failure, remission after high-dose melphalan and autologous stem cell transplantation. Clin Nephrol. 2007;68:171–6.PubMed Ogita M, Hoshino J, Sogawa Y, Sawa N, Katori H, Takemoto F, et al. Multicentric Castleman disease with secondary AA renal amyloidosis, nephrotic syndrome and chronic renal failure, remission after high-dose melphalan and autologous stem cell transplantation. Clin Nephrol. 2007;68:171–6.PubMed
16.
Zurück zum Zitat Nishimoto N, Sasai M, Shima Y, Nakagawa M, Matsumoto T, Shirai T, et al. Improvement in Castleman’s disease by humanized anti-interleukin-6 receptor antibody therapy. Blood. 2000;95:56–61.PubMed Nishimoto N, Sasai M, Shima Y, Nakagawa M, Matsumoto T, Shirai T, et al. Improvement in Castleman’s disease by humanized anti-interleukin-6 receptor antibody therapy. Blood. 2000;95:56–61.PubMed
Metadaten
Titel
Renal complications of Castleman’s disease: report of two cases and analysis of 75 cases
verfasst von
Xiang-Gui Yuan
Wen Hu
Fei-Fei Chen
Bin-Feng Huang
Xiao-Ying Zhao
Publikationsdatum
01.12.2011
Verlag
Springer Japan
Erschienen in
Clinical and Experimental Nephrology / Ausgabe 6/2011
Print ISSN: 1342-1751
Elektronische ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-011-0499-9

Weitere Artikel der Ausgabe 6/2011

Clinical and Experimental Nephrology 6/2011 Zur Ausgabe

Acknowledgment

List of referees

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.